July 24, 2020

OICR research leads to new pancreatic cancer clinical trial with aim to change the standard of care for patients

New pancreatic cancer trial, NeoPancONE, launches across Canada

NeoPancONE

Adapted from Pancreatic Cancer Canada’s press release.

OICR’s PanCuRx team and collaborators have launched NeoPancONE, a Phase II clinical trial that will evaluate a potentially curative treatment strategy for operable pancreatic cancer. The trial, which is supported by Pancreatic Cancer Canada, will recruit patients at 10 cancer centres across the country to evaluate the effectiveness and feasibility of peri-operative chemotherapy – chemo treatment before and after surgery.

Typically, only 50 per cent of pancreatic cancer patients receive chemotherapy after surgery due to a range of personal and health reasons. NeoPancONE will help evaluate whether chemotherapy treatment before surgery can help extend the lives of these individuals.

Continue reading – OICR research leads to new pancreatic cancer clinical trial with aim to change the standard of care for patients